|
- Profiles the new grading system for prostate cancer introduced in 2015
- Fully updated and revised new edition
- Authored by recognized experts in their respective fields
This fully updated and revised new edition provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in prostate cancer. The book reviews new data about molecular characteristics of the disease, profiles the new grading system for prostate cancer introduced in 2015, and provides new perspectives about imaging of prostate cancer, as well as the role of targeted biopsies. The text summarizes the role of biomarkers and MRI in patient selection and management and details the world wide results of active surveillance. Specific chapters address communication and ethical issues, QOL outcomes, economic aspects, and psycho-social aspects of surveillance. The role of focal therapy for low risk disease is summarized, and the data supporting preventive interventions during surveillance reviewed. This text will serve as a very useful resource for physicians and researchers dealing with, and interested in this common malignancy, as it provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. Table of Contents- Cancer Overdiagnosis and Overtreatment
Laurence Klotz - Can We Screen and Still Reduce Overdiagnosis?
Peter Ka-Fung Chiu and Monique J. Roobol - The Role of Fear in Overdiagnosis and Overtreatment
Iona Heath - Ethical and Legal Considerations in Active Surveillance for Prostate Cancer
Lionne D.F. Venderbos - Gleason 6 Tumors Should Still Be Labeled As Cancer
Angelo M. De Marzo and Jonathan I. Epstein - Risk Based Selection for Active Surveillance
Jan F.M. Verbeek, Monique J. Roobol and Ewout W. Steyerberg - Surveillance at the Margins: Management of High Volume Gleason 6, PSA > 10, or Gleason 3+4
Laurence Klotz - How Should Patients on Active Surveillance be Followed?
Frank-Jan H. Drost, Monique J. Roobol, and Leonard P. Bokhorst - Triggers for Intervention
Tuomas Mirtti, Hanna Vasarainen, and Antti Rannikko - MR Imaging in Prostate Tumor Volume Assessment: How Accurate?
Ivo G. Schoots and Theo H. van der Kwast - Can MRI Replace Biopsy in Men on Surveillance?
Francesco Giganti, Vasilis Stavrinides, and Caroline M. Moore - Tissue Based Markers for Risk Prediction
Chad A. Reichard and Eric A. Klein - International AS Registry: The Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative
Sophie M. Bruinsma, Daan Nieboer, Tim Hulsen, Liying Zhang, Rachelle Kirk- Burnnand, Sam Gledhill, and Mark Buzza on behalf of the Movember Foundation’s GAP3 Steering Committee - Better Informed Decision Making to Optimize Patient Selection
Lara Bellardita, Paola Dordoni, Letizia De Luca, Julia Paola Menichetti Delor, Riccardo Valdagni - How Does QOL Compare Between Surveillance and Active Treatment?
Lionne D.F. Venderbos, Stephanie Danielle Brandhof, and Ida J. Korfage - The Potential Benefits of Diet and Physical Activity among Active Surveillance Patients with Low-Burden Prostate Cancer
Stacey A. Kenfield, David Tat, and June M. Chan - Is there a Role for Pharmacologic Manipulation to Prevent Progression in Men on Active Surveillance? The Role of 5-ARIs, Statins, and Metformin
Roy Mano and David Margel - The Update of Active Surveillance around the World: Utilization and Outcomes
Jeffrey J. Tosoian, Ridwan Alam, Abbey Lepor, Stacy Loeb - Tissue Preservation – Active Surveillance and Focal Therapy as Complimentary Strategies
Juan Gomez Rivas and Mark Emberton - The Economics of Active Surveillance for Prostate Cancer
Robert B. Lurvey and Marc A. Dall’Era - Research Questions in Active Surveillance
Laurence Klotz
|
